Dr. Pankaj Taneja is eminent teacher and scientist. He has 24 years of experience at national and international levels in biotechnology. His area of research is in signal transduction pathways in cancer prevention. His group also developed Novel Dmp1-Arf-p53 tumor suppressor pathway in breast and lung cancer. He worked as postdoc fellow and Scientist in Johns Hopkins and Wake Forest Universities, USA. He was also awarded with prestigious presidential Ramalingaswamy fellowship.
Reviewer of manuscript of scientific journals-
BZ Sibuh, S Quazi, H Panday, R Parashar, NK Jha, R Mathur, SK Jha, P Taneja, AK
Jha. (2023). The Emerging Role of Epigenetics in Metabolism and Endocrinology
Biology, 12(2),256.
2. Lohchania B, Christopher AC, Arjunan P, Mahalingam G, Kathirvelu D, Aishwarya
Prasannan A, Venkatesan V, Taneja P, Mohan Kumar Km, Thangavel S. Marepally S.
(2023).Diosgenin enhances liposome-enabled nucleic acid delivery and
CRISPR/Cas9-mediated gene editing by modulating endocytic pathways. Frontiers
in Bioengineering and Biotechnology 10, 1031049
3. SS Biresaw, P Taneja.(2022).Copper nanoparticles green synthesis and
characterization as anticancer potential in breast cancer cells (MCF7) derived from
Prunus nepalensis phytochemicals Materials Today: Proceedings 49, 3501-3509
4. DK Bhardwaj, NK Taneja, P Taneja, P Patel (2022).Phenotypic and genotypic
characterization of multi-drug resistant, biofilm forming, human invasive strain of
Salmonella Typhimurium SMC25 isolated from poultry meat in India. Microbial
Pathogenesis 173, 105830
5. A Joshi, D Bhardwaj, A Kaushik, VK Juneja, P Taneja, S Thakur, Taneja NK (2022).
Advances in multi-omics based quantitative microbial risk assessment in the dairy
sector: A semi-systematic review. Food Research International, 111323
6. BZ Sibuh, S Khanna, P Taneja, P Sarkar, NK Taneja (2021). Molecular docking,
synthesis and anticancer activity of thiosemicarbazone derivatives against MCF-7
human breast cancer cell line Life Sciences 273, 119305
7. P Taneja, S Sharma, VB Sinha, AK Yadav (2021). Advancement of nanoscience in
development of conjugated drugs for enhanced disease prevention Life sciences 268,
118859
8. Taneja P, Sharma S, Sinha, VB, Yadav AK (2021). Advancement of nanoscience in
development of conjugated drugs for enhanced disease prevention. Life Sciences Mar
1;268:118859. doi: 10.1016/j.lfs.2020.118859.
9. Biresaw SS, Damte, SM Taneja P (2020) Green synthesized silver nanoparticles:-a
promising anticancer agent. International Journal of Nanoscience. 19(4): 1-20.
10. Gulzar M, Syed SB, Khan FI, Khan P, Ali, S Hasan GM, Taneja P, Hassan I(2019).
Elucidation of interaction mechanism of ellagic acid to integrin linked kinase.
International Journal of Biological Macromolecules. 122: 1297-1304.
11. Mallakin A, Taneja P, Inoue, K, Ward AN, Dahms H-U (2018). Biochemical
characterization of ratfish (Chimaera montrosa) liver oil; Cytotoxic and antineoplastic
evaluation in cancer cell lines. Integrative Clinical Medicine 2(4): 1-11.
12. Tripathi S, Taneja P, Jha SK (2018). Training on an Appetitive (delay)-conditioning
task enhances Oscillatory waves during sleep in the cortical and amygdalar network.
Frontiers in Behavioural Neuroscience. 12 (260): 1-17.
13. Rattan SS, Taneja P (2018). Revealing the J-coupling in the H-NMR Spectra of
antineoplastic and antimetabolites drugs. Der Pharma Chemica 10(1): 55-58.
14. Gulzar M, Ali S, Khan FI, Khan P, Taneja P, Hassan I (2018). Binding mechanism of
Caffeic acid and simvastatin to the integrin linked kinase for therapeutic implications:
a comparative docking and MD simulation studies. Journal of Biomolecular
Structure and Dynamics 29: 1-37.
15. Onwurah C, Majumder S and Taneja P (2017). Growth Characteristics of Indian and
Nigerian Chlorella pyrenoidosa used as Food Supplement. Biotechology BioScience
Reseach Asia 14(2): 835-841.
16. Fry EA, Taneja P, Inoue K (2017). Oncogenic and tumor suppressive mouse models
of breast cancer engaging Her2/Neu. International Journal of Cancer. 140(3):495-
503.
17. Shivam K, Khan AR, Taneja P (2017). Psychosocial Symptoms and therapy aspects
of Schizophrenia. Airo International Journal 8: 1-25.
18. Khan AR, Taneja P. (2016). In-vivo Inhibition of Glutathione S-Transferase P1 by
Bovine Lactoferricin in Swiss Albino Tumor Bearing Mice. Journal of Applied
Pharmaceutical Science 6 (11):210-213.
19. Khan, AR, Idris ZS, Lawi IA , Dauda D, Taneja P. (2016). Chemoprotective role of
bovine lactoferricin against 7, 12 dimethylbenz (a) anthracene induced skin cancer in
female Swiss albino mice. International Journal of Pharmacy and Pharmaceutical
Science, 8: 215-222.
20. Shivam K, Khan AR, Taneja P (2016). Development in diagnosis and treatment of
Alzheimers disease. IOSR Journal of Pharmacy 6(7): 43-50.
21. Shivam K, Khan AR, Singh NP, Malik BK, Taneja P (2016). Recent advances in
diagnosis and treatment of Schizophrenia. Airo International Journal 8: 1-36.
22. Khan AR, Taneja P. (2015). Cationic Peptide LactoferricinB inhibits Glutathione-
transferase P1 from human placenta and breast cancer cell line MDAMB-231 in
preventing anticancer drug metabolism. International Journal of Pharmacy and
Pharmaceutical Science 7(8); 1-4.
23. Maglic D, Stovall DB, Cline JM, Fry EA, Mallakin A, Taneja P, Caudell DL,
Willingham MC, Sui G, Inoue K. (2015). DMP1β, a splice isoform of the tumour
suppressorDMP1 locus, induces proliferation and progression of breast cancer.
Journal of Pathology 236(1): 90-102.
24. Yadav AK, Vashishta V, Joshi N, Taneja P (2014). AR-A 014418 Used against
GSK3beta Downregulates Expression of hnRNPA1 and SF2/ASF Splicing Factors. J
Oncology.695325. doi: 10.1155/2014/. Epub Jan 2.
25. Fry EA, Taneja P, Maglic D, Zhu S, Sui G, Inoue K. (2013) Dmp1α inhibits
HER2/neu-induced mammary tumorigenesis. PLoS One. ;8(10):e77870.
26. Zhu S, Mott RT, Fry EA, Taneja P, Kulik G, Sui G, Inoue K. (2013). Cooperation
betweenDmp1 loss and cyclin D1 overexpression in breast cancer. Am J Pathol.
183(4):1339-50.
27. Inoue K, Fry EA, Taneja P. (2013). Recent progress in mouse models for tumor
suppressor genes and its implications in human cancer. Clinical Medical Insights:
Oncology. 7; 103-122.
28. Maglic D*, Zhu S*, Fry E*, Taneja P*, Kai F, Kendig RD, Sugiyama T, Miller LD,
Willingham M, Inoue K. (2013). Prognostic value of hDMP1-Arf-hDM2-p53
pathway in breast cancer. Oncogene 32(35):4120-9
* Equal Contribution
29. Taneja P, Zhu S, Maglic D, Fry E, Kendig R, Inoue K (2011). Transgenic and
Knockout mice models to reveal the functions of tumor Suppressor genes. Clinical
Medical Insights: Oncology. 5; 235-257.
30. Taneja P, Maglic D, Sugiyama T, Kai F, Frazier D.P, Kendig R.D,Willingham S,
Inoue K.(2010). Dmp1 is the critical regulator of Her2/Neu P53-Arf signaling.
Cancer Research 70;9084-9094.
31. Taneja P, Maglic D, Sugiyama T, Kai F, Zhu S, Kendig R.D, Fry E, Inoue K.(2010).
Classical and novel prognostic markers of breast cancer and their clinical significance.
Clinical Medical Insights: Oncology 4: 15-34.
32. Mallakin A, Sugiyama T, Kai F, Taneja P, Frazier D, Maglic D Kendig R, Inoue K.
(2010).The Arf inducing transcription factor Dmp1 encodes transcription regulator
Amphiregullin, Thrombospondin1 and JunB. Int J Cancer ,126; 1403-1416.
33. Taneja P, Sugiyama T, Kai F, Frazier D.P, Kendig R.D, Maglic D, Taneja N.K, Inoue
K. (2009). MMTV mouse models for human breast cancer and their diagnostic values.
Expert Reviews Mol Diag. 9 (5),423-440.
34. Prasad S, Taneja P, George S, Shukla Y (2009). Regulation of Cell Signalling
molecules by Natural compounds:Chemopreventive and Chemotherapeutic
Approach.Cancer Therapy. 7, 467-487.
35. Sugiyama T, Taneja P, Frazier DP, Kendig RD, Morgan RL, Matise LA, Lagedrost
SJ, Inoue K. (2008) Oncogenic and non-oncogenic signaling pathways that regulate
Dmp1 (Dmtf1) (review).Clinical Medicine: Oncology,2, 209-219.
36. Inoue K, Sugiyama T, Taneja P, Morgan RL, Frazier DP. (2008) Emerging roles of
DMP1 in lung cancer. Cancer Research, 68, 4487-4490.
37. Taneja P, Mallakin A, Matise LA, Frazier DP, Choudhary M, Inoue K. (2007)
Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-
kappaB subunit p65. Oncogene, 26,7457-7466.
38. Mallakin A*, Sugiyama T*, Taneja P*, Matise LA*, Frazier DP, Choudhary M,
Hawkins GA, D'AgostinoRB Jr, Willingham MC, and Inoue K. (2007) Mutually
exclusive inactivation of DMP1 and Arf/p53 in lung Cancer. Cancer Cell, 12, 381-
394.
* Equal Contribution
39. Mallakin A, Taneja P, Matisie A , Willingham M, Inoue K. (2006) .Expression of
Dmp1 in specific differentiated, non-proliferating cells and its regulation by E2Fs.
Oncogene,25, 7703-7713.
40. Shukla Y, Taneja P, Arora A, Sinha N (2004). Mutagenic Potential of Mancozeb in
Salmonella typhimurium. J Env Pathol. Toxicol. Oncol 23, 294-302.
41. Taneja P, Arora A, Shukla Y. (2003).Antimutagenic effects of black tea in the
Salmonella typhimurium reverse mutation assay .Asian. Pac. J Cancer Prev. 4, 193-
198.
42. Shukla Y, Arora A, Taneja P. (2003). Antigenotoxic potential of certain dietary
constituents. Teratogen. Carcinogen. Mutagen. 23,323-335.
43. Shukla Y, Taneja P # (2002). Anticarcinogenic effect of black tea on pulmonary
tumors in Swiss albino mice. Cancer Lett., 176, 137-141.
44. Shukla Y, Arora A, Taneja P, (2002). Antimutagenic potential of Curcumin on
Chromosomal aberrations in Wistar rats. Mutat. Res. 515,197-202.
45. Shukla Y, Taneja P # . (2002). Antimutagenic effect of garlic extract on Chromosomal
aberrations. Cancer Lett 176, 31-36.
46. Shukla Y, Taneja P # .(2002) Mutagenic evaluation of cypermethrin in mouse dominant
lethal assay.J Env Pathalog Toxicol. Onclol., 21, 259-265.
47. Shukla Y, Taneja P # (2001) Antimutagenic effect of black tea extract using” rodent
dominant lethal mutation assay. Toxicology, 168, 269-274
48. Shukla, Y., Taneja, P # (2000). Mutagenic evaluation of deltamethrin using rodent
dominant lethal assay. Mutat. Res, 467, 119- 127
BOOK CHAPTERS
I. Taneja P, Gulzar M, Taneja NK, Dwarkanath BS and Tripathi RP (2017)
Phytochemicals in Therapy of Radiation Induced Damage and Cancer. Cancer Preventive
and Therapeutic Compounds: Chapter 6 Page 105-124 Gift From Mother Nature
Bentham Publishers eISBN: 978-1-68108-491-6 ISBN: 978-1-68108492-3.
II. Taneja P, Kendig R, Zhu S, Maglic D, Fry S, Inoue K. (2012). Oncogenes and Tumor
Suppressor genes in Small Cell Lung Carcinoma. Lung Diseases-Selected state of art
Reviews: INTECH; ISBN: 978-953-51-0180-2; Pages 148-170
III. K Garg, AR Khan, P Taneja (2021). Recent developments in CCR5 regulation for HIV
cure Advances in Protein Chemistry and Structural Biology 126, 123-149.
IV. NK Taneja, A Singh, DP Shivaprasad, P Taneja, D Sachdev. (2022) Nutraceuticals and
Natural‐Product Derivatives for Disease PreventionHandbook of Nutraceuticals and
Natural Products: Biological, Medicinal, and Medicinal, and Nutritional Properties and
Applications
V. P Taneja, SS Biresaw, N KumraTaneja, SK Jha, B Zeleke, S Srivastava (2022)Advances
in fermented foods and therapeuticsInnovations in Fermentation and
Phytopharmaceutical Technologies, 341-358.
